MedTrace Logo

EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)

NCT00211978 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2008-01-08

No results posted yet for this study

Summary

The purpose of this study is to determine if calcium acetate (PhosLo) can control serum phosphorus in pre-dialysis patients with moderate to severe impairment of kidney function.

Conditions

Interventions

DRUG

calcium acetate

667 mg gelcaps, 1-3 t.i.d. (titrated to serum phosphorus level)

DRUG

placebo

gelcap, 1-3 t.i.d. (titrated to serum phosphorus level)

Sponsors & Collaborators

  • Nabi Biopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Wajeh Y Qunibi, M.D. · University of Texas Health Science Center San Antonio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2006-06-30
Completion
2006-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00211978 on ClinicalTrials.gov